AstraZeneca Pharma India (NSE:ASTRAZEN) Cyclically Adjusted PB Ratio: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ASTRAZEN AstraZeneca Pharma India Ltd NSE:ASTRAZEN
87 GF Score
Price ₹7,106.50
GF Value ₹11,461.05
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AstraZeneca Pharma India Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Pharma India  (NSE:ASTRAZEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Pharma India Cyclically Adjusted PB Ratio Related Terms


AstraZeneca Pharma India Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca Pharma India's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Pharma India Cyclically Adjusted PB Ratio Chart

AstraZeneca Pharma India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.56 22.50 31.53 44.44 34.59

AstraZeneca Pharma India Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 43.26 0.00 34.59 0.00

NSE:ASTRAZEN vs ZTS: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Pharma India Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Cyclically Adjusted PB Ratio falls into.


NSE:ASTRAZEN
87GF Score
AstraZeneca Pharma India Ltd NSE:ASTRAZEN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Pharma India Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca Pharma India's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AstraZeneca Pharma India's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

AstraZeneca Pharma India Quarterly Data

Book Value per Share CPI Adj_Book
201609 66.948 105.961 105.739
201612 0.000 105.196 0.000
201703 89.148 105.196 141.826
201706 0.000 107.109 0.000
201709 86.417 109.021 132.658
201712 0.000 109.404 0.000
201803 98.772 109.786 150.567
201806 0.000 111.317 0.000
201809 105.385 115.142 153.176
201812 0.000 115.142 0.000
201903 120.320 118.202 170.356
201906 0.000 120.880 0.000
201909 131.833 123.175 179.121
201912 0.000 126.235 0.000
202003 145.776 124.705 195.635
202006 0.000 127.000 0.000
202009 162.012 130.118 208.379
202012 0.000 130.889 0.000
202103 182.468 131.771 231.746
202106 0.000 134.084 0.000
202109 189.158 135.847 233.034
202112 0.000 138.161 0.000
202203 204.556 138.822 246.603
202206 0.000 142.347 0.000
202209 217.473 144.661 251.593
202212 0.000 145.763 0.000
202303 235.476 146.865 268.333
202306 0.000 150.280 0.000
202309 261.986 151.492 289.423
202312 0.000 152.924 0.000
202403 284.768 153.035 311.420
202406 0.000 155.789 0.000
202409 271.740 157.882 288.048
202412 0.000 158.323 0.000
202503 308.140 157.552 327.318
202506 0.000 159.755 0.000
202509 319.600 162.289 329.581
202512 0.000 163.281 0.000
202603 349.116 164.272 355.672
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued. The current stock price of ₹7,106.50 is trading 38% below its estimated GF Value™ of ₹11,461.05. GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.

Key valuation signals for NSE:ASTRAZEN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹11,461.05 vs. price of ₹7,106.50 (38% below fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Pharma India Business Description

Other Exchanges 506820:India
Address Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
87GF Score

Get the complete analysis for NSE:ASTRAZEN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7,106.50
Price
₹11,461.05
GF Value